3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Cisplatin
30
Magnetic Resonance Spectroscopy
21
Radiotherapy
20
pembrolizumab
18
Specimen Handling
17
Cetuximab
16
Radiotherapy, Intensity-Modulated
11
Paclitaxel
11
Carboplatin
11
Fluorouracil
10
Biopsy
10
1,2-diaminocyclohexaneplatinum II citrate
10
Radiation
9
Platinum
9
Drug Therapy
9
Taxes
7
Surgical Procedures, Operative
7
Celecoxib
7
X-Rays
6
Standard of Care
6
Sentinel Lymph Node Biopsy
6
Surveys and Questionnaires
5
Nivolumab
5
cemiplimab
4
Metformin
4
Fluorodeoxyglucose F18
4
Docetaxel
4
Chemoradiotherapy
4
(225)Ac-DOTA-c(RGDyK)
4
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mouth Neoplasms
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn